Amneal Pharmaceuticals announced Thursday Tasos Konidaris was appointed as senior vice president, chief financial officer, effective March 12.
Konidaris succeeds Todd Branning, who will remain available to the company through March 31.
“We are confident Tasos’s insights and expertise will further advance our ongoing efforts to unlock operating efficiencies and strategically deploy capital to reinvigorate the business. We look forward to working closely with him as we build on Amneal’s strong foundation to drive long-term growth and value for our stakeholders in 2020 and beyond,” Amneal co-Chief Executive Officers Chirag Patel and Chintu Patel said.
“With its compelling diversification strategy, extensive portfolio of marketed commercial products and exciting pipeline of generics and specialty therapeutics products, I believe Amneal is building momentum and well-positioned for success,” Konidaris said. “I am excited to work closely with Chirag, Chintu and the rest of the talented leadership team during this important time for the company.”
Konidaris most recently served as chief financial officer and as a board member of Alcresta Therapeutics Inc., a medical therapeutics company. Prior to that, he served as executive vice president, chief financial officer and head of corporate development of Ikaria Inc., a pharmaceutical company. Konidaris also previously served seven years as senior vice president and chief financial officer of Dun & Bradstreet Corp., as well as held various roles of increasing responsibility at Schering-Plough Corp., Pharmacia Corp., Novartis Corp. and Bristol-Myers Squibb.